Maintenance Bee-Venom Immunotherapy Administered at 6-Month Intervals Does Not Protect Against re-Stings

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00684476

Enrollment

Registered

2008-05-26

Start date

2004-06-30

Completion date

2006-05-31

Last updated

2008-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Venom Allergy

Brief summary

Maintenance venom immunotherapy administered at 6-month intervals to bee-venom allergic patients failed to provide protection from systemic reactions after sting challenges. These patients should continue their immunotherapy at 1-3 month intervals.

Detailed description

Background: The intervals at which maintenance venom immunotherapy (MVIT) is administered have been progressively extended over the years. Objective: To examine whether the administration of bee venom (BV) maintenance dose (MD) at 6-month interval is safe and efficacious. Methods: The usual 3-month interval at which venom allergic patients were receiving their MVIT was gradually extended to 6 months. Systemic reactions (SRs) to immunotherapy injections or to field stings were regularly recorded. BV allergic patients were deliberately sting-challenged after reaching the 6-month interval.

Interventions

DRUGvenom immunotherapy

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

6 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Venom allergy

Exclusion criteria

* none

Design outcomes

Primary

Measure	Time frame
whether the administration of bee venom (BV)	—
maintenance dose (MD) at 6-month interval is safe and	—
efficacious.	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026